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Abstract
Autoinflammatory diseases are rare illnesses characterized by apparently unprovoked inflammation without high-
titer auto-antibodies or antigen-specific T cells. They may cause neurological manifestations, such as meningitis
and hearing loss, but they are also characterized by non-neurological manifestations. In this work we studied a
30-year-old man who had a chronic disease characterized by meningitis, progressive hearing loss, persistently
raised inflammatory markers and diffuse leukoencephalopathy on brain MRI. He also suffered from chronic recurrent
osteomyelitis of the mandible. The hypothesis of an autoinflammatory disease prompted us to test for the presence
of mutations in interleukin-1−pathway genes and to investigate the function of this pathway in the mononuclear
cells obtained from the patient. Search for mutations in genes associated with interleukin-1−pathway demonstrated
a novel NLRP3 (CIAS1) mutation (p.I288M) and a previously described MEFV mutation (p.R761H), but their
combination was found to be non-pathogenic. On the other hand, we uncovered a selective interleukin-6
hypersecretion within the central nervous system as the likely pathogenic mechanism. This is also supported by the
response to the anti-interleukin-6−receptor monoclonal antibody tocilizumab, but not to the recombinant
interleukin-1−receptor antagonist anakinra. Exome sequencing failed to identify mutations in other genes known to
be involved in autoinflammatory diseases. We propose that the disease described in this patient might be a
prototype of a novel category of autoinflammatory diseases characterized by prominent neurological involvement.
Keywords: Anakinra, Aseptic meningitis, NLRP3 (CIAS1), Hearing loss, Interleukin-1, Interleukin-6,
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Background
Autoinflammatory diseases are rare monogenic or multi-
factorial (complex) illnesses, characterized by apparently
unprovoked inflammation without high-titer auto-
antibodies or antigen-specific T cells [1,2]. Autoinflam-
matory diseases may cause neurological manifestations,
such as meningitis and hearing loss [3,4], but they are
also characterized by non-neurological manifestations,
such as cutaneous and articular symptoms and signs
[1,5]. Among the already recognized autoinflammatory
disorders are autosomal dominant diseases related to
NLRP3 (CIAS1) mutations, including chronic infantile
neurologic cutaneous articular syndrome (CINCA) and
Muckle-Wells syndrome (MWS), and the autosomal
recessive (AR) familial Mediterranean fever (FMF) due
to MEFV mutations. There are, however, patients
with autoinflammatory phenotypes without known
genetic mutations [2]. Here, we pinpoint an autoinflam-
matory disease due to selective IL-6 hypersecretion and
characterized by predominant central nervous system
(CNS) involvement.
Case presentation
In March 2006, a 24-year-old Italian male patient was
admitted for chronic headache (more severe in the
morning), intermittent, low-grade fever and recurrent
episodes of double vision that first occurred in March
2004. He also had a single tonic-clonic seizure in July
2004, for which no anti-epileptic therapy was started.
His familial and past histories were unremarkable,
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except for chronic recurrent osteomyelitis of the man-
dible manifesting with repetitive mandibular pain and
swelling, since the age of 20. Neurological examination
revealed bilateral papilledema and increased deep tendon
reflexes. No extra-neurological signs were present. Labora-
tory investigations revealed raised inflammatory markers
and mild anemia. Brain magnetic resonance imaging (MRI)
showed diffuse T2-weighted hyperintensity in the white
matter, patchy involvement of the basal ganglia and thalami,
and arachnoid cysts. Brain computed tomography (CT)
showed tiny subcortical calcifications (Figure 1 and
Additional file 1). Lumbar puncture revealed increased
opening pressure (40 cmH2O), raised proteins and mild
pleocytosis (see Table 1 for details). Despite extensive inves-
tigations (see Additional file 1), no infection was found and
no autoimmune marker was demonstrated, except
for fluctuating (negative to 1:640) titers of antinu-
clear antibodies (ANAs). Steroid therapy, started in
October 2006, caused rapid clinical improvement
with disappearance of headache, fever, papilledema,
double vision, and mandibular osteomyelitis. However,
headache reappeared when prednisone was tapered
down to 30 mg/day, despite the co-administration of
azathioprine 200 mg/day, and the patient developed
progressive hearing loss, postural tremor and cushingoid
features. Laboratory investigations still showed raised
inflammatory markers, mild anemia, elevated cere-
brospinal fluid (CSF) white-cell count (with a variable
number of polymorphonuclear leukocytes), and pro-
teinuria (1 g/24 h). Renal biopsy revealed only fusion
of podocyte processes.
Chronic autoinflammatory disease was hypothesized,
despite the lack of extra-neurological manifestations ex-
cept for mandibular osteomyelitis.
Methods
DNA Sampling and genetic analyses
Genomic DNA for gene sequencing was isolated from
peripheral blood mononuclear cells (PBMCs) using
standard methods, and then stored at +4°C. Mutations in
NLRP3 (exon 3) [NM_001243133, RefSeq], IL6 [NM_000600,
RefSeq], LIN28A [NM_024674, RefSeq], MEFV (exons
1to 10) [NM_000243, RefSeq], MIRLET7A3 [NR_029478,
RefSeq], MVK (exons 2, and 8 to 11) [NM_000431, RefSeq],
and TNFRSF1A (exons 2–4) [NM_001065, RefSeq] were
searched for by direct sequencing. In particular, to search for
mutations in the IL6 gene, all six exons, including the 50-UTR
Figure 1 Neuroradiological findings in different examinations. Last magnetic resonance imaging (MRI) study (A and B, axial T2-weighted
images; C, apparent diffusion coefficient (ADC) map) shows diffuse hyperintensities in the white matter, patchy involvement of the basal ganglia
and thalami, and arachnoid cysts (arrows). ADC is increased, consistent with increased water content in the brain tissue. Comparison of MRI
studies obtained 4 years apart (D, E, coronal T2-weighted images) shows progression of the leukoencephalopathy, decrease in size of the
subarachnoid spaces along the convexity, and slight enlargement of the ventricles. Recent computed tomography (CT) scan (F) demonstrates
tiny subcortical calcifications (arrows). See Additional file 1 for further details.
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Table 1 Key clinical features of our patient from 2004 to 2011








































No No No Dexameth
(8 mg/day




















ESR (≤20 mm) 104 110 110 35 90 85 100 80 10 N/D
CRP (≤5 mg/L) 61 70.7 62 3 45 39 80 53 1 N/D
White Cell (%PMN; %L)
(3,500 to 10,000/μL;
40 to 74%; 19 to 48%)












(14 to 16 g/dl)
11.7 10.6 10.1 11.8 12.8 11.4 11.5 11.7 15.8 N/D
IL-6 in serum
(≤10 pg/ml)
N/A N/A N/A N/A 44.23 22.4* 11.42 38.7 127 44.8
CSF pressure (5 to 1
5 cmH2O)
N/D N/D 40 40 35 N/D N/D 24 N/D Normal
CSF White Cell/μl
(L; PMN) (≤4/μl)
16 (N/D) 40 (25; 7) 40 (24; 12) 2.6 24 (12; 10) 45 (20; 12) 63 (10; 47)2 32 (26; 5) 65 (25; 22) 8 (7.3; 0.6)
CSF proteins
(10 to 45 mg/dl)
63 84.1 98.4 33.0 73.9 90.6 98.2 123.2 102.2 54.5
CSF albumin / serum
albumin × 1,000 (≤6.5)
6.37 12.36 15.51 8.37 12.08 18.26 21.18 20.59 16.86 11.12
Link IgG index (0.1
to 0.7); ReiberIgG
index (≤0)
0.66; N/A 0.79; -5.07 0.96; 22.30 0.50; -21.95 1.90; 104.57 1.01; 25,61 1.09; 38.59 1.49; 118.81 0.77; -9.9 0.63; -14.89
OBs (negative) No (type 1) No (type 1) No (type 1) No (type 1) No (type 1) Yes (type 3) No (type 4) Yes (type 3) No (type 4) No (type 1)
IL-6 in CSF
(≤10 pg/ml)
N/A N/A N/A 232.8 4544 N/A 9585 5389 7874 85
ANAs (negative) N/D 1:320 1:640 1:640 1:40 1:320 1:80 1:80 1:40 N/D
Proteinuria (0 to
150 g/day)










1Laboratory data obtained from another hospital.2The predominance of polymorphonuclear leukocytes (PMN) in this CSF sample helped us to hypothesize a possible autoinflammatory disease. The values shown in
parentheses in the first column on the left are the normal values. ANAs, antinuclear antibodies; AZA, azathioprine; CRP, C-reactive protein; CSF, cerebrospinal fluid; Dexameth, dexamethasone; Methylpred, methylprednisone;




















and 30-UTR, and their flanking intron regions were amplified
by the PCR method, purified and directly sequenced. Primers
and PCR conditions are available on request. The c.864C>G
(p.I288M) mutation in NLRP3 and the c.2282G>A (p.R761H)
mutation in MEFV were also searched for in the patient’s
family members (that is, the father, mother, two sisters and
one brother) by direct sequencing.
Exome analysis
To prepare a next-generation sequencing library, gen-
omic DNA was extracted from PBMCs, and randomly
fragmented by a Covaris Adaptive Focused Acoustics™
(AFA) instrument to obtain an average fragment size of
200 to 300 base pairs. Then, the genomic DNA frag-
ments were end-repaired, adenylated, linked to Illumina-
specific adapter sequences, and amplified by PCR.
Exome capture was performed using the TruSeq™
Exome Enrichment Kit (Illumina, San Diego, CA, USA).
Sequencing was performed on the Illumina Genome
Analyzer HiSeq2000 following the manufacturer’s
instructions. The average coverage was 20-fold. The
sequencing reads were aligned to the human reference
genome hg19 using the Burrows-Wheeler Aligner (BWA)
software. We analyzed the data using the Genome Analysis
Toolkit (GATK) variant pipeline with respect to 1,000
Genomes Data, Single Nucleotide Polymorphism Database
(dbSNP) and in-house data, and we used the SnpEff
software to predict the effects of sequence variants.
Body fluid collection
CSF and/or serum of the patient, patient family mem-
bers and unrelated controls were used for laboratory
analyses on the same day of the sampling or were stored
at −40°C in the serum and CSF bank of the Neurological
Institute ‘Carlo Besta’. Control CSF was obtained from
patients with non-inflammatory neurological diseases
(that is, brain tumors, neurodegenerative and heredo-
metabolic diseases).
Determination of cytokines and IL-6-R
IL-1β and soluble IL-6R (sIL-6R) were determined by
ELISAs (Human IL-1β/IL-1F2 Quantikine ELISA Kit,
catalogue number DLB50, and Human IL-6 R alpha
Quantikine ELISA Kit, catalogue number DR600; R&D
Systems, Minneapolis, MN, USA; www.rndsystems.com).
In addition, CSF IL-1β was determined by a high sensi-
tivity immunoassay (Human IL-1β/IL-1F2 Quantikine
HS Immunoassay, catalogue number HSLB00C, R&D Sys-
tems). CSF2/GM-CSF, IFN-γ, IL-6, IL-8, IL-17A, and TNF-
α were determined by the Human Inflammatory Cytokines
Multi-Analyte ELISArray Kit from SABiosciences (cata-
logue number MEH-004A; SABiosciences, Frederick, MD,
USA; www.sabiosciences.com), and IL-8 and TNF-α
concentrations were also determined by ELISA (GE
Healthcare Europe GmbH, Milan, Italy; www.gelifesciences.
com). IL-6 concentrations were determined by an
electrochemiluminescent immunoassay (IL6 Elecsys, cata-
logue number 05109442190, Roche Diagnostics, Mann-
heim, Germany; www.roche.de) performed using a Cobas
E601 analyzer (Roche Diagnostics), whereas the level of IL-
6 mRNA was investigated by real-time PCR using standard
methods, and 18S as housekeeping gene. In the monocytes
of the patient and ten healthy controls, membrane-bound
IL-6R was roughly quantified by western blot using an anti-
human IL-6 Rα antibody (Human IL-6 R alpha Affinity
Purified Polyclonal Ab, Goat IgG, AF-227-NA, R&D
Systems) and anti-beta-actin antibody as internal control
(Monoclonal Anti-β-Actin antibody produced in mouse-
clone AC-15, purified immunoglobulin, buffered aqueous
solution, catalogue number A1978, Sigma-Aldrich, Milan,
Italy; www.sigmaaldrich.com).
Cell cultures
Monocytes were obtained from the peripheral blood of
the patient, the patient’s family members, and healthy
controls. In order to determine the IL-1β and IL-6 secre-
tion in vitro, monocytes were cultured in RPMI Medium
1640 (Invitrogen, Carlsbad, CA, USA; www.invitrogen.
com) containing 10% fetal bovine serum (FBS, Gibco –
Invitrogen, Carlsbad, CA, USA) for approximately 18
hours at 37°C/5%CO2, and then they were activated by 1
μg/ml of lipopolysaccaride (LPS, catalogue number
L6529, Sigma-Aldrich) for 3 hours at 37°C in fresh RPMI
Medium 1640. For the evaluation of the sole IL-1β se-
cretion, the monocytes were subsequently incubated in
the presence of 1 mM ATP (catalogue number A6419,
Sigma-Aldrich) for an additional 15 minutes. Super-
natants were collected for quantification of IL-1β
and IL-6; for the evaluation of IL-6 mRNA levels,
RNA was isolated from the monocytes using the
QIAamp RNA Blood Mini Kit (catalogue number
52304; Qiagen, Milan, Italy; www.qiagen.com); for
the evaluation of membrane-bound IL-6R, proteins
were isolated using Laemmli Buffer.
Statistical analyses
Statistical analyses were performed using GraphPad
Prism 5.00 for Windows, GraphPad Software, San Diego
California USA, www.graphpad.com.
Ethical approval and patient consent
Anakinra was administered off-label, the experimental
treatment with tocilizumab was approved by the inde-
pendent ethics committee of the IRCCS Foundation, C.
Besta Neurological Institute, and the patient provided
written informed consent for both treatments.
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Results
A novel c.864C>G (p.I288M) NLRP3 missense mutation
and the previously described c.2282G>A (p.Arg761His)
MEFV mutation were found. No mutation was found in
the TNFRSF1A and MVK genes, which are associated
with other autoinflammatory diseases, and karyotype
and array-CGH analysis (see Additional file 1) were nor-
mal [1,6]. The p.I288M mutation - not reported in
the INFEVERS registry (http://fmf.igh.cnrs.fr/ISSAID/
infevers/) - is located in exon 3, where most of the
pathogenic NLRP3 mutations are located; the isoleucine
residue at position 288 is conserved in mammals and
birds, and its substitution with methionine is non-
conservative. Prediction using the sorting intolerant
from tolerant (SIFT) software indicates that the p.I288M
substitution is of probable functional importance to the
protein. Moreover, only one MEFV mutation was found
in a subset of FMF patients, although FMF is tradition-
ally considered an autosomal recessive disease [7], and
both NLRP3-related diseases and FMF are IL-1β activa-
tion disorders, which may cause aseptic meningitis [3,4].
Hence, the combination of these two mutations could
actually be pathogenic. However, segregation analysis in
the proband’s family showed that neither the p.I288M
NLRP3 mutation alone nor the combination of the two
mutations segregated with the phenotype (Figure 2).
Moreover, i) there was no response to the IL-1 receptor
antagonist anakinra (Amgen Inc), which is efficacious in
IL-1β activation disorders; ii) circulating IL-1β concen-
tration was similar in the serum of the patient (0.19 ±
0.3 pg/ml, n=12) and ten unrelated healthy controls
(0.16±0.3 pg/ml); iii) no IL-β was detected in the CSF of
the patient, even with a high sensitivity immunoassay;
iv) no difference in IL-1β secretion was observed com-
paring patient and control monocytes under resting con-
ditions and after LPS alone or LPS followed by ATP
stimulation (Figure 3A) [8]. Therefore, atypical IL-1β ac-
tivation disorders were forcibly excluded.
Therefore, we measured CSF2/GM-CSF, IFN-γ, IL-6,
IL-8, IL-17α, and TNF-α in the patient’s serum samples,
and we found that, among these cytokines, only IL-6
was increased. Indeed, the IL-6 concentration evaluated
in seven independent samples of the patient’s serum,
each obtained ≥4 weeks apart, was 37.20 ± 18.17 pg/ml
(nv ≤10 pg/ml). On the basis of this finding, and given
that the patient has been complaining of neurological
symptoms, we also measured IL-6 in patient’s CSF sam-
ples, and we found that its concentration was much
higher than in serum. Indeed, the CSF IL-6 concentra-
tion evaluated in five independent samples of the pa-
tient’s CSF, each obtained ≥4 weeks apart, was 5,432 ±
2,742 pg/ml (nv ≤10 pg/ml) (Figure 3B) [9]. For com-
parison, the CSF IL-6 concentration evaluated in 17
patients with non-inflammatory neurological diseases
(that is,thirteen with brain tumors and four with
neurodegenerative diseases) was 10.4 ± 7.8 pg/ml, with a
value ≤10 pg/ml in eleven of seventeen patients. Finally,
we measured both IL-8 and TNF-α in at least one patient’s
CSF sample, and we found that TNF-α was undetectable,
whereas IL-8 was increased (490.3 pg/ml, nv<32),
Figure 2 Absence of co-segregation of the mutations I288M inNLRP3(CIAS1) and R761H inMEFVwith the disease phenotype in the
patient’s family members.
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Figure 3 (See legend on next page.)
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probably because IL-8 is induced by IL-6 from CSF mono-
nuclear cells [10]. Overall, these data suggest that IL-6
played a key role in the pathogenesis of the disease under
investigation.
As a consequence, the patient was treated with the anti-
IL-6 receptor (IL-6R) monoclonal antibody tocilizumab
(Roche), 8 mg/kg every 28 days. Ten days after the first
tocilizumab administration, the blood inflammatory
markers normalized (Table 1). Moreover, the steroid intake
was rapidly reduced without worsening of symptoms.
Progressive disappearance of cushingoid features and
postural tremor was observed and the patient definitely
stopped complaining about headache after dividing the
daily prednisone dose (12.5 mg/day) between morning
(7.5 mg/day) and evening (5 mg/day). However, CSF
parameters remained abnormal, and serum IL-6 concen-
tration, which was evaluated in 23 independent samples of
the patient’s serum (each obtained about 4 weeks apart),
markedly increased to 178.8±84.14 pg/ml (nv ≤10.0pg/ml)
(Figure 3B). This increase is probably due to the inhibition
of the clearance of IL-6 from serum by tocilizumab. In
fact, the main elimination pathway of IL-6 from serum
may be from the binding of IL-6 to IL-6R, including the
soluble form. As a consequence, IL-6 may accumulate in
serum when the anti-IL-6R monoclonal antibody
tocilizumab binds to the IL-6-binding site of its receptor
[11]. In contrast, no significant change in the IL-6
concentration was found in four independent samples
of the patient’s CSF (mean value 7221±2212 pg/ml)
(Figure 3B), but we detected a reduction of CSF IL-8
concentration in two independent samples of the pa-
tient’s CSF (from 490.3 pg/ml before tocilizumab to
157.0 pg/ml and, then, 53.0 pg/ml (nv<32.0) under
tocilizumab). This reduction suggests that tocilizumab
may diffuse into CSF, and inhibit the IL-6-mediated
effects (though slightly).
The high CSF IL-6/serum IL-6 ratio suggests that IL-6
is produced in the CNS and/or CSF, from which it dif-
fuses into blood (Figure 3B and Table 1). To further
corroborate this hypothesis, the IL-6 secretion between
patient and control monocytes under resting conditions
and after activation with LPS was compared, and no sig-
nificant difference was observed (Figure 3C). Moreover,
no clear-cut difference was found between the levels of
IL-6 mRNA after LPS stimulation (see Additional file 2).
To identify the cause of the chronic IL-6 hypersecretion,
we searched for mutations in the IL6 gene, including its
50- and 30-UTRs, and in LIN28A and MIRLET7A3, which
encode for molecules involved in the IL-6 regulatory
pathway [12], with no mutation found. We ruled out
mutations in the LPIN2, PSMB8 and SH3BP2 genes by
using exome analysis, despite these genes having been as-
sociated with autoinflammatory diseases with different
phenotypes. We investigated the serum concentration of
soluble IL-6R (sIL-6R), which mediates the IL-6 clearance,
but no clear-cut abnormality was found before or under
tocilizumab (see Additional file 3) [11]. Moreover, we
found that the amount of membrane-bound IL-6R in the
patient’s monocytes was similar to that of healthy controls
(not shown). Finally, there was no infection by Human
Herpes Virus 8 (HHV8), which contains an IL-6 homolo-
gous gene [13].
Discussion
We report a case of chronic inflammatory disease, which
can be considered as the prototype of a novel category
of autoinflammatory diseases characterized by primary
CNS involvement. The key manifestations are chronic
meningitis, progressive hearing loss, diffuse white-matter
hyperintensity, and persistently raised inflammatory
markers. The pathogenic mechanism of this disease is a
selective and chronic IL-6 hypersecretion. Indeed, no
other cytokine among those investigated was consist-
ently increased in CSF and serum, and the anti-IL-6R
monoclonal antibody tocilizumab was partially able to
counteract the phenotype. The persistence of abnormal
CSF parameters is likely due to the low permeability of
the blood brain barrier for tocilizumab.
(See figure on previous page.)
Figure 3 In vitro IL-1β secretion, serum and cerebrospinal fluid (CSF) IL-6 in the patient, and in vitro IL-6 secretion. (A) IL-1β secretion
from monocytes of the proband (II-4), his family members (I-1, I-2, II-1 and II-2) and five unrelated healthy controls (HC1-5) after 3 hours of LPS
incubation, or 15 minutes of ATP exposure following LPS stimulation, was quantified by ELISA. Results are expressed as pg/ml per 106 cells. For
the proband the values are the mean of three experiments. Unlike monocytes from patients bearing a pathogenic NLRP3 mutation [8],
monocytes from the proband and his family members, harboring the p.I288M NLRP3 (I-2 and II-1), p.R761H MEFV (I-1), or both (II-2 and II-4)
mutations, displayed a pattern of IL-1β secretion similar to healthy controls, and characterized by further IL-1β secretion following ATP
induction. (B) Serum and CSF IL-6 in our patient before and under tocilizumab (TCZ). Before tocilizumab, IL-6 concentration was evaluated in
patient’s serum samples (n=7) and CSF samples (n=5), each obtained ≥4 weeks apart. IL-6 was raised in serum (37.20±18.17, normal value (nv)
≤10 pg/ml) and CSF (5432±2742, nv ≤10) despite a high dose of prednisone. CSF IL-6 concentration was very high, and the mean ratio of CSF
IL-6/serum IL-6 was about 146, suggesting that IL-6 is produced in central nervous system (CNS). Under tocilizumab (and prednisone reduction ),
serum IL-6 concentration significantly increased (178.8±84.14 (n=23) versus 37.20±18.17 (n=7), P= 0.0003; Mann–Whitney test); the slight increase
of CSF IL-6 concentration was not significant (7221±2212 (n=4) versus 5432±2742 (n=5), P= 0.2857; Mann–Whitney test). (C) In vitro IL-6 secretion.
IL-6 amounts from monocytes of our patient (Pt) and 13 healthy controls (HCs) are similar under resting conditions (RCs; 8.043±3.343 pg/ml (n=7)
versus 12.36±8.3) and after LPS stimulation (LPS; 1209±956.6 pg/ml (n=7) versus 772.7±663.2), further suggesting that the deregulation of IL-6
production occurs primarily in CNS. See Additional file 2 for IL-6 mRNA level analysis.
Salsano et al. Journal of Neuroinflammation 2013, 10:29 Page 7 of 10
http://www.jneuroinflammation.com/content/10/1/29
Despite extensive laboratory investigations, the cause
of IL-6 hypersecretion was not identified. Although pa-
tients suffering from autoinflammatory diseases (AID)
who are double heterozygotes for mutations in two
known AID-associated genes have been reported [14], it
is amazing that we found two mutations in known AID-
associated genes (NLRP3 and MEFV) that were proved
to be unrelated to the disease under investigation. How-
ever, we cannot exclude that the p.I288M NLRP3 variant
and the p.R761H MEFV mutation contribute to the in-
flammatory phenotype in the presence of other genetic
or permissive environmental factors triggering IL-6
hypersecretion [2]. Microglia, astroglia, or both, are the
likely source of IL-6 as suggested by IL-6 CSF/serum ra-
tio [5], and by the lack of abnormal IL-6 hypersecretion
by patient monocytes in vitro. The condition of our pa-
tient, therefore, might be analogous to the neurological
disease induced in transgenic mice by IL-6 cerebral
overexpression [15,16].
The CNS hypersecretion of IL-6 may cause: 1) an
increased blood–brain barrier permeability, leading
to subtle edema. This may explain why there are no
focal or diffuse CNS symptoms, and the somato-
sensory and motor-evoked potentials are near normal
(see Additional file 1), despite extensive MRI abnor-
malities; 2) CSF inflammation with increased intra-
cranial pressure, and 3) inner ear damage [5,17].
Moreover, IL-6 diffusion to the blood compartment
may cause the increase of inflammatory markers and
chronic anemia (through hepcidin increase), fusion
of the feet of podocytes, and proteinuria. Finally, it should
be noted that chronic recurrent multifocal osteomyelitis
and cherubism are both autoinflammatory diseases [1],
suggesting that the chronic recurrent osteomyelitis of the
mandible observed in our case may be expression of an
autoinflammatory state.
ANA positivity with titer fluctuations (up to 1:640)
may suggest a role of autoimmunity in the pathogenesis
of the disease, with proportions differing at different
phases [18]. However, ANAs may be present in healthy
subjects and patients with a variety of diseases, including
non-rheumatic diseases [19], and their level may be
increased by IL-6 [20]. Therefore, in our case, ANA
positivity might be a clinically non-specific finding
related to the chronic inflammation.
Chronic monogenic autoinflammatory diseases, including
CINCA, autoimmune diseases including neurolupus, and
complex diseases with no specific antigen/antibody but
with evidence of cellular inflammation, such as neuro-
Behçet disease and primary angiitis of the CNS, may cause
chronic aseptic meningitis, with or without evidence of
diffuse white matter abnormalities on brain MRI [5,21-23].
In our case, however, the criteria proposed for the diagnosis
of these diseases are not satisfied despite long-term follow
up, and the pattern of cytokine production is peculiar. In
particular, CNS systemic lupus erythematosus was excluded
on the basis of the American College of Rheumathology
criteria because of the absence of a wide range of extra-
neurological manifestations, such as arthritis, dermatitis,
and glomerulonephritis, and because of the presence of
persistently raised inflammatory markers, leukocytosis and
slightly increased (or normal) complement levels (see
Additional file 1) [24]. Neuro-Behçet disease was excluded
because of the absence of symptoms consistent with focal
or multifocal CNS dysfunction, and absence of extra-
neurological features, namely, oral and genital ulcerations
and eye and skin lesions. Moreover, HLA-B*51 was absent,
the levels of other pro-inflammatory cytokines were normal
[25], and no response to anakinra was obtained [26].
Primary angiitis of the CNS was excluded because of lack
of neurological deficit, presence of constantly raised inflam-
matory markers, and young age at onset [27]. Infectious
diseases were also excluded since there was no worsening
after the long corticosteroid and immunosuppressive
treatment. Castleman disease, a rare disorder biologically
characterized by raised serum IL-6 levels, was excluded on
the basis of clinical features, unremarkable total-body
(18F)-fluorodeoxyglucose-positron emission tomography/
computed tomography, and absence of serum HHV8 DNA
and anti-HHV8 antibodies [12].
Conclusions
This report demonstrates a case of autoinflammatory
neurological disease due to IL-6 hypersecretion with
aseptic chronic meningitis as the key feature. We suggest
that all patients with non-infective chronic meningitis of
unknown etiology should be investigated for IL-6
hypersecretion.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Additional files
Additional file 1: Neuroradiological, electrophysiological and
laboratory data.
Additional file 2: Figure showing IL-6 mRNA levels.
Additional file 3: Figure showing soluble IL-6 receptor
concentrations before and after tocilizumab.
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